Patents Assigned to YUNGJIN PHARM. CO., LTD.
-
Patent number: 11684610Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of solid cancers or blood cancers such as acute leukemia or chronic leukemia, including, as an active ingredient, a 1,2-naphthoquinone derivative compound or a pharmaceutically acceptable salt thereof, wherein the 1,2-naphthoquinone derivative compound has excellent effects in killing cancer cells of various solid cancers, acute leukemia, and chronic leukemia, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of cancer, in particular, solid cancers, acute leukemia, or chronic leukemia.Type: GrantFiled: April 4, 2019Date of Patent: June 27, 2023Assignee: YUNGJIN PHARM. CO., LTD.Inventors: Ki Ryang Kweon, Jun Young Heo, Min Ho Shong, Jeong Su Han, Min Jeong Ryu
-
Patent number: 10766882Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.Type: GrantFiled: April 23, 2018Date of Patent: September 8, 2020Assignee: YUNGJIN PHARM CO., LTD.Inventors: Whee Seong Lee, Mi Jung Lee, Bo Jung Kim, Tae Cheul Roh, Seung Hoon Lee, Kyu Dae Lee, You-Hui Lee, Tae Hwan Kwak
-
Patent number: 9975883Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in Claim 1.Type: GrantFiled: December 30, 2014Date of Patent: May 22, 2018Assignee: YUNGJIN PHARM. CO., LTD.Inventors: Whee Seong Lee, Mi Jung Lee, Bo Jung Kim, Tae Cheul Roh, Seung Hoon Lee, Kyu Dae Lee, You-Hui Lee, Tae Hwan Kwak
-
Publication number: 20160193265Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.Type: ApplicationFiled: February 1, 2016Publication date: July 7, 2016Applicants: Jeonnam Bioindustry Foundation, YUNGJIN PHARM.CO., LTD.Inventors: Chul Yung CHOI, Sang O PAN, Hee Jin SEOL, Gyu Ok LEE, Ka Hyon PARK, Hee Sook KIM, Wook Jin JANG, Hyun KIM, Dong Wook LEE, Sun Oh KIM, Jae Gap KIM
-
Patent number: 9370542Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.Type: GrantFiled: May 16, 2012Date of Patent: June 21, 2016Assignees: JEONNAM BIOINDUSTRY FOUNDATION, YUNGJIN PHARM.CO., LTD.Inventors: Chul Yung Choi, Sang O Pan, Hee Jin Seol, Gyu Ok Lee, Ka Hyon Park, Hee Sook Kim, Wook Jin Jang, Hyun Kim, Dong Wook Lee, Sun Oh Kim, Jae Gap Kim
-
Patent number: 9273359Abstract: The present disclosure relates to a method of assessing a subject's susceptibility to a vascular disease. The method may comprise providing a concentrated population of extracellular vesicles contained in a biological material obtained from a subject, processing the concentrated population to determine if the concentrated population contains a 16S rRNA sequence of Staphylococcus, and upon determining that the concentrated population contains a 16S rRNA sequence of Staphylococcus, further determining that the subject is potentially susceptible to a vascular disease.Type: GrantFiled: January 9, 2015Date of Patent: March 1, 2016Assignee: YUNGJIN PHARM. CO., LTD.Inventors: Yong Song Gho, Yoon Keun Kim, Eun Young Lee, Sung Wook Hong, Ji Hyun Kim, Seng Jin Choi
-
Patent number: 9180101Abstract: Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least one release control base selected from the group consisting of water-insoluble polymer, and water-soluble viscous polymer, and a pharmaceutically acceptable carrier; and, an immediate release part comprising a second active pharmaceutical ingredient and a pharmaceutically acceptable carrier.Type: GrantFiled: May 16, 2011Date of Patent: November 10, 2015Assignee: YUNGJIN PHARM CO., LTD.Inventors: Dong-Joon Oh, Byoung-Ki Kim, Byung-Kwan Moon, Ji-Seok Yoo, Dae-Hee Shin, Byung-Hwan Ryoo
-
Publication number: 20140205691Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.Type: ApplicationFiled: May 16, 2012Publication date: July 24, 2014Applicants: YUNGJIN PHARM.CO., LTD., JEONNAM BIOINDUSTRY FOUNDATIONInventors: Chul Yung Choi, Sang O Pan, Hee Jin Seol, Gyu Ok Lee, Ka Hyon Park, Hee Sook Kim, Wook Jin Jang, Hyun Kim, Dong Wook Lee, Sun Oh Kim, Jae Gap Kim
-
Publication number: 20110217374Abstract: Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least one release control base selected from the group consisting of water-insoluble polymer, and water-soluble viscous polymer, and a pharmaceutically acceptable carrier; and, an immediate release part comprising a second active pharmaceutical ingredient and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 16, 2011Publication date: September 8, 2011Applicant: YUNGJIN PHARM. CO., LTD.Inventors: Dong-Joon OH, Byoung-Ki Kim, Byung-Kwan Moon, Ji-Seok Yoo, Dae-Hee Shin, Byung-Hwan Ryoo